Welcome to our dedicated page for AVITA Medical SEC filings (Ticker: AVHHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AVITA Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AVITA Medical's regulatory disclosures and financial reporting.
AVITA Medical, Inc. (RCEL) officer David D. O'Toole, the CFO, reported an amended insider transaction. On June 12, 2026, he purchased 2,000 shares of AVITA Medical common stock at $3.97 per share in an open market or private transaction. This amendment corrects the original filing’s transaction code from “A” to “P”. Following the purchase, his directly held position is 152,927 shares, which includes unvested RSUs.
AVITA Medical, Inc. entered into a Global Amendment with Stedical Scientific, Inc. on August 5, 2026, modifying their distribution and manufacturing arrangements for PermeaDerm. AVITA will pay a $500,000 fee for a right of first offer and refusal to expand its exclusive distribution territory to all or part of the European Union, the United Kingdom, and/or Australia.
AVITA’s revenue share from PermeaDerm sales will rise to 67% for sheet products, with higher sharing if AVITA’s gross margin exceeds 50%, and to 80% for glove products, with higher sharing if gross margin exceeds 35%. For 2026, AVITA must achieve total PermeaDerm revenue sharing payments of $1.0 million, with 20% minimum annual growth in such payments through 2030, while all prior minimum revenue sharing requirements are waived.
Stedical may commercialize PermeaDerm in certain U.S. markets not served by AVITA, purchasing product at a 10% premium to AVITA’s actual manufacturing costs. For PermeaDerm sold by Stedical outside the U.S., primarily in Asia, AVITA will charge $200 per carton plus a 10% manufacturing fee, subject to a reasonable volume cap.
AVITA Medical, Inc. disclosed its decision on how often to seek stockholder advisory approval of executive compensation following its June 3, 2026 annual meeting. Stockholders supported holding say-on-pay votes every year, with 9,545,151 votes for 1 year, 924,743 for 2 years, 650,252 for 3 years, 581,759 abstentions, and 3,890,542 broker non-votes.
Consistent with this outcome and the board’s recommendation, the board determined that AVITA Medical will hold future advisory votes on named executive officer compensation every year until the next required frequency vote, which will occur no later than the company’s 2032 annual meeting of stockholders.
AVITA Medical, Inc., a wound-care company focused on its RECELL platform, reported higher revenues but continued losses for the quarter and six-months ended June 30, 2026. Total revenues were $21,702 (in thousands) for the quarter and $40,953 (in thousands) year-to-date, up from $18,418 and $36,932 (in thousands) a year earlier. Net loss narrowed to $7,663 (in thousands) for the quarter and $18,274 (in thousands) for six months, versus $9,920 and $23,779 (in thousands) in 2025.
As of June 30, 2026, the company had cash, cash equivalents, and marketable securities of $11.1 million and a stockholders’ deficit of $27,838 (in thousands), with a $46,659 (in thousands) loan facility recorded as a current liability. Management determined there is substantial doubt about the ability to continue as a going concern over the next twelve months, and the auditor’s review report referenced this uncertainty.
In January 2026 AVITA entered a five-year senior secured credit facility of up to $60.0 million, drawing $50.0 million and using part of the proceeds to refinance a prior loan; the interest rate was 11.5% as of June 30, 2026, and covenants include a $5.0 million minimum cash balance and net revenue tests. The company also signed a 10-year BARDA agreement providing about $4.0 million in access and maintenance fees over the term, plus potential procurement revenue, and continues to build its portfolio through Cohealyx and PermeaDerm distribution and manufacturing arrangements.
AVITA Medical reported Q2 2026 net revenue of $21.7 million, up 18% year over year and 13% sequential, driven by RECELL, Cohealyx, PermeaDerm, and international sales. Gross profit margin was 81.9%, while operating expenses fell 6% to $24.6 million, narrowing the net loss to $7.7 million, or $0.25 per share.
Net cash used declined to approximately $3.2 million, with cash, cash equivalents, and marketable securities of about $11.1 million at quarter end. Management raised 2026 net revenue guidance to $86–$89 million versus $71.6 million in 2025 and expects cash flow breakeven in Q4 2026. The balance sheet shows total liabilities of $75.6 million exceeding assets of $47.8 million, resulting in a stockholders’ equity deficit of $27.8 million. CMS also released proposed 2027 Medicare payment updates that would establish national physician payment and higher facility rates for RECELL if finalized.
O'Toole David D reported acquisition or exercise transactions in this Form 4 filing.
AVITA Medical CFO David D. O'Toole received a grant of 2,000 shares of common stock at a reference value of $3.97 per share. This was a compensation-related award, not an open-market purchase, and increased his directly held stake to 152,927 shares, including unvested RSUs.
AVITA Medical, Inc. director Woody Joseph Fralin made an open-market purchase of the company’s common stock. On June 9, 2026, he bought 5,200 shares at $4.00 per share, bringing his direct holdings to 107,961 shares, which the disclosure notes include unvested RSUs.
AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of common stock in open-market transactions. The purchases occurred at prices of $4.18 and $4.20 per share. A footnote indicates the reported holdings include unvested restricted stock units (RSUs).
AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of the company’s Common Stock in open-market transactions. The purchases on June 3, 2026 were made at prices of $4.0899 and $4.0999 per share.
After these trades, Fralin directly holds 92,761 shares of AVITA Medical common stock, which the disclosure notes includes unvested restricted stock units (RSUs). These are straightforward open-market purchases, increasing his direct equity stake in the company.
AVITA Medical, Inc. director Robert McNamara reported receiving new equity compensation. He was granted 22,214 restricted stock units, each representing one share of common stock, subject to time-based vesting. These RSUs vest 12 months after the January 20, 2026 grant date, following stockholder approval obtained on June 3, 2026.
McNamara was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share. The options were approved by the board on January 5, 2026, have a grant date of January 20, 2026, become exercisable starting January 20, 2027, and expire on January 20, 2036. Following these awards, he directly owns 108,985 shares of common stock, including unvested RSUs.